Marta Bruix

Marta Bruix

Auto-generated profile, based on publicly available information

Marta Bruix

Instituto de Química-Física Rocasolano, IQFR-CSIC, Madrid, Spain

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 1993 in Biochemistry
Verified
Journal Article
Closed access
MBM. Bruix
M. Bruix
M Angeles JimenezM Angeles Jimenez
M Angeles Jimenez
JSJ. Santoro
J. Santoro
Carlos GonzalezCarlos Gonzalez
Carlos Gonzalez
FCF. J. Colilla
F. J. Colilla
MRM. Rico
M. Rico

26 September 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Carlos GonzalezCarlos Gonzalez
Carlos Gonzalez
GLGrant M. Langdon
Grant M. Langdon
MBMarta Bruix
Marta Bruix
AGAntonio Galvez
Antonio Galvez
EVEva Valdivia
Eva Valdivia
MRManuel Rico
Manuel Rico
The solution structure of bacteriocin AS-48, a 70-residue cyclic polypeptide from Enterococcus faecalis , consists of a globular arrangement of five α-helices enclosing a compact hydrophobic core. The head-to-tail union lies in the middle of helix 5, a fact that is shown to have a pronounced effect on the stability of the three-dimensional structure. Positive charges in the side chains of residues in helix 4 and in the turn linking helix 4 to helix 5 form a cluster that most probably determine its antibacterial activity by promoting pore formation in cell membranes. A similar five-helix structural motif has been found in the antimicrobial NK-lysin, an effector polypeptide of T and natural killer (NK) cells. Bacteriocin AS-48 lacks the three disulfide bridges characteristic of the saposin fold present in NK-lysin, and has no sequence homology with it. Nevertheless, the similar molecular architecture and high positive charge strongly suggest a common mechanism of antibacterial action.

1 February 1993 in Journal of Molecular Biology
Verified
Journal Article
Closed access
JSJ Santoro
J Santoro
Carlos GonzalezCarlos Gonzalez
Carlos Gonzalez
MBM Bruix
M Bruix
JNJ L Neira
J L Neira
JNJ L Nieto
J L Nieto
MRM Rico
M Rico

1 July 2010 in Biophysical Journal
Verified
Journal Article
Closed access
LMLeonor Morgado
Leonor Morgado
MBMarta Bruix
Marta Bruix
MPMiguel Pessanha
Miguel Pessanha
YLYuri Y. Londer
Yuri Y. Londer
Carlos A. SalgueiroCarlos A. Salgueiro
Carlos A. Salgueiro

1 January 1996 in Biochemistry
Verified
Journal Article
Closed access
MRManuel Rico
Manuel Rico
MBMarta Bruix
Marta Bruix
Carlos GonzalezCarlos Gonzalez
Carlos Gonzalez
RMRafael Ignacio Monsalve
Rafael Ignacio Monsalve
RRRosalía Rodríguez
Rosalía Rodríguez

26 January 2016 in PLOS Biology
Verified
Journal Article
Open access
PDF file
RHRubén Hervás
Rubén Hervás
LLLiying Li
Liying Li
AMAmitabha Majumdar
Amitabha Majumdar
MFMaría del Carmen Fernández-Ramírez
María del Carmen Fernández-Ramírez
JUJay R. Unruh
Jay R. Unruh
MCMariano Carrión-Vázquez
Mariano Carrión-Vázquez
Amyloids are ordered protein aggregates that are typically associated with neurodegenerative diseases and cognitive impairment. By contrast, the amyloid-like state of the neuronal RNA binding protein Orb2 in Drosophila was recently implicated in memory consolidation, but it remains unclear what features of this functional amyloid-like protein give rise to such diametrically opposed behaviour. Here, using an array of biophysical, cell biological and behavioural assays we have characterized the structural features of Orb2 from the monomer to the amyloid state. Surprisingly, we find that Orb2 shares many structural traits with pathological amyloids, including the intermediate toxic oligomeric species, which can be sequestered in vivo in hetero-oligomers by pathological amyloids. However, unlike pathological amyloids, Orb2 rapidly forms amyloids and its toxic intermediates are extremely transient, indicating that kinetic parameters differentiate this functional amyloid from pathological amyloids. We also observed that a well-known anti-amyloidogenic peptide interferes with long-term memory in Drosophila. These results provide structural insights into how the amyloid-like state of the Orb2 protein can stabilize memory and be nontoxic. They also provide insight into how amyloid-based diseases may affect memory processes. Amyloids are ordered protein aggregates typically associated with neurodegenerative diseases, such as Alzheimer disease and Parkinson disease, which usually result in cognitive impairment. However, the amyloid state of the neuronal RNA binding protein Orb2 shows a quite opposite behaviour: instead of impairment, it is associated with memory consolidation. Here, we have characterized the structural features of Orb2 from the monomer to the amyloid state in order to determine why it shows this unexplained puzzling behaviour. Surprisingly, we find that Orb2 shares many structural traits with pathological amyloids. However, Orb2 rapidly forms amyloids, and its toxic intermediates are transient. Furthermore, we find that an anti-amyloidogenic peptide that blocks the initial structural transitions in pathological amyloids also blocks Orb2 amyloid formation and memory consolidation. Our results provide structural insights into how Orb2 amyloids can mediate stable memory while being nontoxic and how amyloid-based diseases may affect memory processes. They also suggest a new pharmacological approach for blocking memory consolidation.